Search
Abrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigational[A244549] Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. … Patients with moderate-to-severe atopic dermatitis report reduced quality of life and often face limited treatment options.
Pantothenic acid
go.drugbank.com/drugs/DB01783ApprovedInvestigationalNutraceuticalVet approvedFor many animals, pantothenic acid is an essential nutrient as it is required to synthesize coenzyme-A (CoA), as well as to synthesize and metabolize proteins, carbohydrates, and fats. … Pantothenic acid, also called pantothenate or vitamin B5 (a B vitamin), is a water-soluble vitamin discovered by Roger J. Williams in 1919.
Mixtures: Folika-T, TL-FolateCantharidin
go.drugbank.com/drugs/DB12328ApprovedInvestigational[A32892] Nevertheless, it gained its first FDA approval on Jul 21, 2023, under the brand name YCANTH™ by Verrica Pharmaceuticals for the treatment of molluscum contagiosum in adult and pediatric patients … [A32891, A32892] For its natural purpose, the male blister beetle secretes and presents the cantharidin to a female beetle as a copulatory gift during mating.
Roxadustat
go.drugbank.com/drugs/DB04847ApprovedInvestigationalIt works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transcription factor that stimulates red blood cell production in response to low oxygen levels. … Roxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease.
Gepirone
go.drugbank.com/drugs/DB12184ApprovedAlthough earlier clinical trials showed promising results for gepirone, its formulation as an immediate-release tablet necessitates frequent administration due to the short half-lives. … [A261670,A261675,A182315] Gepirone was approved by the FDA on September 28, 2023, under the brand name EXXUA for the treatment of adults with major depressive disorder.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeOrlistat
go.drugbank.com/drugs/DB01083ApprovedInvestigationalObesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. … In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required.
Polatuzumab vedotin
go.drugbank.com/drugs/DB12240ApprovedInvestigational[L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141] … Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells.
Rocuronium
go.drugbank.com/drugs/DB00728ApprovedInvestigationalIt is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery … [Sugammadex] is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium.
Metoprolol
go.drugbank.com/drugs/DB00264ApprovedInvestigational[A175162] Metoprolol was developed since 1969 by US Pharmaceutical Holdings I and FDA approved in 1978.[L5527] … [T274] To this date, it is one of the preferred beta-blockers in general clinical guidelines and it is widely prescribed in the Netherlands, New Zealand, and the US.
Products: METOHEXAL-SUCC 47.5MG DO, METOHEXAL-SUCC 23.75MG DO